Invasion and Increased Expression of S100A4 and CYR61 in Mesenchymal Transformed Breast Cancer Cells Is Downregulated by GnRH

ABS-201 may block prolactin receptors in hair, potentially reducing androgen receptors and affecting hair loss. It could also aid collagen synthesis and stem cell pathways, similar to GHK-Cu.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Exosomes from mesenchymal stem cells can increase hair growth by enhancing anagen duration and hair shaft thickness through the Wnt/beta-catenin pathway. Phase 2 trials show improved hair counts over 24 weeks.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.